Pfizer/Medarex Antibody Collaboration Includes Cross-Licensing Of Melanoma Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Medarex expects cross-licensing anti-CTLA-4 products will enhance opportunities for future products by clearing up potential intellectual property issues. Pfizer will make up-front payments totaling $110 mil. to secure 50 antibody products over 10 years.
You may also be interested in...
Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma
The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles